<p>根據 Axa S.A.在最近向證券交易委員會提交的 Form 13F 文件，該公司在第二季度增持了 Vertex Pharmaceuticals Incorporated（納斯達克代碼：VRTX - 免費報告）6.5% 的股份。這家機構投資者在此期間購買了額外的 10,477 股後，持有 171,270 股該製藥公司的股票。Axa S.A.在最近的報告期末持有的 Vertex Pharmaceuticals 股份約佔 0.07%，價值 76,249,000 美元。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
<ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
<p>其他對沖基金最近也對該公司的持倉進行了調整。Activest Wealth Management 在第一季度購買了價值約 25,000 美元的 Vertex Pharmaceuticals 新頭寸。Clal Insurance Enterprises Holdings Ltd 在第一季度將其在 Vertex Pharmaceuticals 的股份增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 現在擁有 55 股該製藥公司的股票，價值 27,000 美元，此前在上個季度又購買了 45 股。Access Investment Management LLC 在第二季度購買了價值 27,000 美元的 Vertex Pharmaceuticals 新頭寸。Flaharty Asset Management LLC 在第一季度購買了價值 32,000 美元的 Vertex Pharmaceuticals 新股份。最後，Legacy Investment Solutions LLC 在第二季度購買了價值 29,000 美元的 Vertex Pharmaceuticals 新股份。目前，90.96% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Vertex Pharmaceuticals 股價下跌 3.0%</h2>
<p>納斯達克：VRTX 週二開盤價為 442.04 美元。該公司的市值為 1,121.5 億美元，市盈率為 31.17，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 12 個月低點為 362.50 美元，12 個月高點為 519.68 美元。該股票的 50 日簡單移動平均線為 423.07 美元，200 日簡單移動平均線為 425.36 美元。</p>
<ul>
<li>2025 年最佳生物技術股票推薦</li>
</ul>
<p>Vertex Pharmaceuticals（納斯達克：VRTX - 獲取免費報告）最近在 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.80 美元，超出市場共識預期的 4.58 美元，超出 0.22 美元。該公司季度收入為 30.8 億美元，而市場共識預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。與去年同期相比，該公司的收入增長了 11.0%。去年同期，該公司每股收益為 4.38 美元。整體來看，股票研究分析師預測 Vertex Pharmaceuticals Incorporated 在本財年將發佈 15.63 美元的每股收益。</p>
<h2>分析師設定新目標價</h2>
<p>VRTX 最近成為多份研究報告的主題。巴克萊將 Vertex Pharmaceuticals 的目標價從 408.00 美元上調至 414.00 美元，並在 11 月 4 日的研究報告中給予該股票 “持平” 的評級。花旗集團將 Vertex Pharmaceuticals 的目標價從 550.00 美元上調至 575.00 美元，並在 10 月 2 日的研究報告中給予該股票 “買入” 的評級。Leerink Partners 將 Vertex Pharmaceuticals 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 9 月 25 日的研究報告中將該公司的目標價從 458.00 美元下調至 456.00 美元。摩根大通將 Vertex Pharmaceuticals 的目標價從 517.00 美元上調至 530.00 美元，並在 10 月 8 日的研究報告中給予該公司 “增持” 的評級。最後，Stifel Nicolaus 將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並在 11 月 4 日的研究報告中對該股票設定了 “持有” 的評級。有兩位分析師給予該股票 “強烈買入” 評級，十六位給予 “買入” 評級，十位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 495.53 美元。</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p><strong>閲讀我們關於 VRTX 的最新報告</strong></p>
<h2>Vertex Pharmaceuticals 內部活動</h2>
<p>在其他新聞中，執行副總裁 Charles F. Wagner, Jr.在 12 月 3 日星期三出售了 14,000 股該股票。該股票以平均價格 456.00 美元出售，總交易額為 6,384,000.00 美元。交易後，該執行副總裁持有 37,725 股公司股票，價值約為 17,202,600 美元。這代表其持倉減少了 27.07%。該交易已在向證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，董事長 Jeffrey M. Leiden 在 12 月 3 日星期三出售了 63,781 股 Vertex Pharmaceuticals 股票。該股票以平均價格 449.20 美元出售，總價值為 28,650,425.20 美元。出售完成後，董事長持有 24,026 股公司股票，價值 10,792,479.20 美元。該交易使其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 151,073 股公司股票，價值 67,326,816 美元。0.20% 的股票由內部人士持有。</p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>在 52 周高點盈利交易股票</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>三隻提供優厚股息收益的天然氣股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
<p><strong>想看看其他對 VRTX 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Vertex Pharmaceuticals Incorporated（NASDAQ:VRTX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>Axa S.A. 在第二季度將其在 Vertex Pharmaceuticals 的股份增加了 6.5%，目前持有 171,270 股，價值 7625 萬美元。分析師們為 Vertex 設置了新的價格目標，花旗集團將其目標提高至 575 美元，摩根大通則提高至 530 美元。該股票的平均評級為 “適度買入”，共識價格目標為 495.53 美元。內部人士活動包括執行副總裁 Charles Wagner 出售了 14,000 股</p>

<p>Axa S.A. grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 171,270 shares of the pharmaceutical company's stock after purchasing an additional 10,477 shares during the period. Axa S.A. owned approximately 0.07% of Vertex Pharmaceuticals worth $76,249,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據 Axa S.A.在最近向證券交易委員會提交的 Form 13F 文件，該公司在第二季度增持了 Vertex Pharmaceuticals Incorporated（納斯達克代碼：VRTX - 免費報告）6.5% 的股份。這家機構投資者在此期間購買了額外的 10,477 股後，持有 171,270 股該製藥公司的股票。Axa S.A.在最近的報告期末持有的 Vertex Pharmaceuticals 股份約佔 0.07%，價值 76,249,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下盈利</li>
</ul>
</div><p>Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Access Investment Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $27,000. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the first quarter worth $32,000. Finally, Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金最近也對該公司的持倉進行了調整。Activest Wealth Management 在第一季度購買了價值約 25,000 美元的 Vertex Pharmaceuticals 新頭寸。Clal Insurance Enterprises Holdings Ltd 在第一季度將其在 Vertex Pharmaceuticals 的股份增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 現在擁有 55 股該製藥公司的股票，價值 27,000 美元，此前在上個季度又購買了 45 股。Access Investment Management LLC 在第二季度購買了價值 27,000 美元的 Vertex Pharmaceuticals 新頭寸。Flaharty Asset Management LLC 在第一季度購買了價值 32,000 美元的 Vertex Pharmaceuticals 新股份。最後，Legacy Investment Solutions LLC 在第二季度購買了價值 29,000 美元的 Vertex Pharmaceuticals 新股份。目前，90.96% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Vertex Pharmaceuticals Trading Down 3.0%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股價下跌 3.0%</h2>
</div><p>NASDAQ:VRTX opened at $442.04 on Tuesday. The company has a market cap of $112.15 billion, a price-to-earnings ratio of 31.17 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The stock has a fifty day simple moving average of $423.07 and a 200-day simple moving average of $425.36.</p>
<div class="lb-trans"><p>納斯達克：VRTX 週二開盤價為 442.04 美元。該公司的市值為 1,121.5 億美元，市盈率為 31.17，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 12 個月低點為 362.50 美元，12 個月高點為 519.68 美元。該股票的 50 日簡單移動平均線為 423.07 美元，200 日簡單移動平均線為 425.36 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技術股票推薦</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The firm's revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $4.38 EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（納斯達克：VRTX - 獲取免費報告）最近在 11 月 3 日星期一發布了季度財報。該製藥公司報告季度每股收益為 4.80 美元，超出市場共識預期的 4.58 美元，超出 0.22 美元。該公司季度收入為 30.8 億美元，而市場共識預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。與去年同期相比，該公司的收入增長了 11.0%。去年同期，該公司每股收益為 4.38 美元。整體來看，股票研究分析師預測 Vertex Pharmaceuticals Incorporated 在本財年將發佈 15.63 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>VRTX has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 2nd. Leerink Partners upgraded Vertex Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and decreased their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. JPMorgan Chase &amp; Co. raised their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus cut their target price on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $495.53.</p>
<div class="lb-trans"><p>VRTX 最近成為多份研究報告的主題。巴克萊將 Vertex Pharmaceuticals 的目標價從 408.00 美元上調至 414.00 美元，並在 11 月 4 日的研究報告中給予該股票 “持平” 的評級。花旗集團將 Vertex Pharmaceuticals 的目標價從 550.00 美元上調至 575.00 美元，並在 10 月 2 日的研究報告中給予該股票 “買入” 的評級。Leerink Partners 將 Vertex Pharmaceuticals 的評級從 “市場表現” 上調至 “跑贏大盤”，並在 9 月 25 日的研究報告中將該公司的目標價從 458.00 美元下調至 456.00 美元。摩根大通將 Vertex Pharmaceuticals 的目標價從 517.00 美元上調至 530.00 美元，並在 10 月 8 日的研究報告中給予該公司 “增持” 的評級。最後，Stifel Nicolaus 將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並在 11 月 4 日的研究報告中對該股票設定了 “持有” 的評級。有兩位分析師給予該股票 “強烈買入” 評級，十六位給予 “買入” 評級，十位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 495.53 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p><strong>Read Our Latest Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 VRTX 的最新報告</strong></p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 內部活動</h2>
</div><p>In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the transaction, the executive vice president owned 37,725 shares of the company's stock, valued at approximately $17,202,600. This represents a 27.07% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the sale, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Charles F. Wagner, Jr.在 12 月 3 日星期三出售了 14,000 股該股票。該股票以平均價格 456.00 美元出售，總交易額為 6,384,000.00 美元。交易後，該執行副總裁持有 37,725 股公司股票，價值約為 17,202,600 美元。這代表其持倉減少了 27.07%。該交易已在向證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，董事長 Jeffrey M. Leiden 在 12 月 3 日星期三出售了 63,781 股 Vertex Pharmaceuticals 股票。該股票以平均價格 449.20 美元出售，總價值為 28,650,425.20 美元。出售完成後，董事長持有 24,026 股公司股票，價值 10,792,479.20 美元。該交易使其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。在過去三個月中，內部人士出售了 151,073 股公司股票，價值 67,326,816 美元。0.20% 的股票由內部人士持有。</p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變的 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>在 52 周高點盈利交易股票</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>三隻提供優厚股息收益的天然氣股票</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 VRTX 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Vertex Pharmaceuticals Incorporated（NASDAQ:VRTX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

安盛股份有限公司購買了福泰製藥公司（Vertex Pharmaceuticals Incorporated）的 10,477 股股票 $VRTX